Notice: SCAC Restructuring

The Stanford Securities Class Action Clearinghouse (SCAC) is currently under construction and is temporarily unavailable as it undergoes updates and improvements. The Clearinghouse is expected to return as part of the Stanford Rock Center for Corporate Governance in Winter 2026.

During this period, updates and new filings will not be available.

For urgent inquiries, please contact rockprograms@law.stanford.edu.

Processing your request


please wait...

Case Page

 

Case Status:    DISMISSED  
—On or around 11/20/2017 (Notice of voluntarily dismissal)
Current/Last Presiding Judge:  
Hon. Charles R. Breyer

Filing Date: August 09, 2017

SciClone Pharmaceuticals, Inc. ("SciClone") is a US-based, China-focused specialty pharmaceutical company with therapies for oncology, infectious diseases and cardiovascular, urological, respiratory, and central nervous system disorders.

According to the Complaint, on June 8, 2017, SciClone announced that they had entered into a definitive agreement with affiliates of the Buyer Consortium on June 7, 2017, under which Silver Biotech Investment Limited, an affiliate of the Buyer Consortium, through its wholly-owned subsidiary, Silver Delaware Investment Limited, will acquire all of the outstanding shares of SciClone in an all-cash transaction (the “Proposed Transaction”).

The Complaint alleges that on August 2, 2017, Defendants issued materially incomplete and misleading disclosures in the Form PREM14A Preliminary Proxy Statement filed with the SEC in connection with the Proposed Transaction.

This case was voluntarily dismissed on November 20, 2017.

Protected Content


Please Log In or Sign Up for a free account to access restricted features of the Clearinghouse website, including the Advanced Search form and the full case pages.

When you sign up, you will have the option to save your search queries performed on the Advanced Search form.